Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OMNi-BiOTiC 10 AAD
- Development stage
- Unknown
- Lead developer
- Institut AllergoSan
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
OMNi-BiOTiC 10 AAD is a multi-strain probiotic dietary supplement developed specifically to prevent and treat antibiotic-associated diarrhea (AAD) and restore intestinal flora during and after antibiotic therapy. It contains ten scientifically selected and clinically studied strains of probiotic bacteria: Lactobacillus acidophilus W55 and W37, Lactobacillus paracasei W72, Lactobacillus rhamnosus W71, Lactobacillus salivarius W24, Lactobacillus plantarum W62, Enterococcus faecium W54, Bifidobacterium bifidum W23, Bifidobacterium lactis W18, and Bifidobacterium longum W51. The product works by replenishing gut microbiota, inhibiting the proliferation of harmful pathogens such as Clostridium difficile, and reducing toxin release by those pathogens. It is recommended during and after antibiotic therapy, and has demonstrated efficacy in clinical and preclinical studies in the prevention of AAD, improvement of microbiome balance, and reduction of systemic inflammation[1][2][3][5][7][8].
- Brand names
- OMNi-BiOTiC 10 AADOMNi-BiOTiC10 AADOMNi-BiOTiC-10 AAD
- Other names
- OMNi BiOTiC AAD10
Beyond the preview
Go deeper on OMNi-BiOTiC 10 AAD.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OMNi-BiOTiC 10 AAD.